{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:07:32Z","timestamp":1783163252728,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40120-024-00682-x","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T08:16:17Z","timestamp":1733300177000},"page":"227-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Burden of Myasthenia Gravis in the Czech\u00a0Republic: Analysis of the Nationwide Patient Registry"],"prefix":"10.1007","volume":"14","author":[{"given":"Stanislav","family":"Voh\u00e1\u0148ka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Tichop\u00e1d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Hor\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Junkerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michala","family":"Jakub\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Pi\u0165ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"T\u00fdblov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Vla\u017en\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katar\u00edna","family":"Brecikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Cudny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"682_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.001","author":"JJGM Verschuuren","year":"2013","unstructured":"Verschuuren JJGM, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, Gomez AM, de Baets MH, Losen M. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013. https:\/\/doi.org\/10.1016\/j.autrev.2013.03.001.","journal-title":"Autoimmun Rev"},{"key":"682_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3.","journal-title":"Lancet Neurol"},{"key":"682_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","volume":"73","author":"A Heldal","year":"2009","unstructured":"Heldal A, Owe J, Gilhus N, Romi F. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009;73:150\u20131. https:\/\/doi.org\/10.1212\/WNL.0b013e3181ad53c2.","journal-title":"Neurology"},{"key":"682_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JND-140045","volume":"2","author":"J Deenen","year":"2015","unstructured":"Deenen J, Horlings C, Verschuuren J, Verbeek A, van Engelen B. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015;2:73\u201385.","journal-title":"J Neuromuscul Dis"},{"key":"682_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1819","author":"E Westerberg","year":"2020","unstructured":"Westerberg E, Punga AR. Epidemiology of myasthenia gravis in Sweden 2006\u20132016. Brain Behav. 2020. https:\/\/doi.org\/10.1002\/brb3.1819.","journal-title":"Brain Behav"},{"key":"682_CR6","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2016.57.2.419","author":"HS Lee","year":"2016","unstructured":"Lee HS, Lee HS, Shin HY, Choi YC, Kim SM. The epidemiology of myasthenia gravis in Korea. Yonsei Med J. 2016. https:\/\/doi.org\/10.3349\/ymj.2016.57.2.419.","journal-title":"Yonsei Med J"},{"key":"682_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2015.10.009","author":"A Breiner","year":"2016","unstructured":"Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2016. https:\/\/doi.org\/10.1016\/j.nmd.2015.10.009.","journal-title":"Neuromuscul Disord"},{"key":"682_CR8","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-829593","author":"LH Phillips","year":"2004","unstructured":"Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol. 2004. https:\/\/doi.org\/10.1055\/s-2004-829593.","journal-title":"Semin Neurol"},{"key":"682_CR9","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2020-0145","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021. https:\/\/doi.org\/10.25122\/jml-2020-0145.","journal-title":"J Med Life"},{"key":"682_CR10","doi-asserted-by":"publisher","DOI":"10.1159\/000487886","author":"I Martinka","year":"2018","unstructured":"Martinka I, Fulova M, Spalekova M, Spalek P. Epidemiology of myasthenia gravis in Slovakia in the years\u00a01977\u20132015. Neuroepidemiology. 2018. https:\/\/doi.org\/10.1159\/000487886.","journal-title":"Neuroepidemiology"},{"key":"682_CR11","doi-asserted-by":"publisher","DOI":"10.1159\/000328863","author":"F Pallaver","year":"2011","unstructured":"Pallaver F, Riviera AP, Piffer S, et al. Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology. 2011. https:\/\/doi.org\/10.1159\/000328863.","journal-title":"Neuroepidemiology"},{"key":"682_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019. https:\/\/doi.org\/10.1177\/1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"key":"682_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14675","author":"C Tran","year":"2021","unstructured":"Tran C, Biswas A, Mendoza M, Katzberg H, Bril V, Barnett C. Performance of different criteria for refractory myasthenia gravis. Eur J Neurol. 2021. https:\/\/doi.org\/10.1111\/ene.14675.","journal-title":"Eur J Neurol"},{"key":"682_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26694","author":"L Harris","year":"2019","unstructured":"Harris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America Registry analysis. Muscle Nerve. 2019. https:\/\/doi.org\/10.1002\/mus.26694.","journal-title":"Muscle Nerve"},{"key":"682_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420932035","author":"V V\u00e9lez-Santamar\u00eda","year":"2020","unstructured":"V\u00e9lez-Santamar\u00eda V, Nedkova V, D\u00edez L, Homedes C, Alberti MA, Casasnovas C. Eculizumab as a promising treatment in thymoma-associated myasthenia gravis. Ther Adv Neurol Disord. 2020. https:\/\/doi.org\/10.1177\/1756286420932035.","journal-title":"Ther Adv Neurol Disord"},{"key":"682_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26447","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019. https:\/\/doi.org\/10.1002\/mus.26447.","journal-title":"Muscle Nerve"},{"key":"682_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, et al. International Consensus Guidance for management of myasthenia gravis: 2020 update. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000011124.","journal-title":"Neurology"},{"key":"682_CR18","first-page":"242","volume":"75","author":"J Pi\u0165ha","year":"2012","unstructured":"Pi\u0165ha J, Bedna\u0159\u00edk J, Zapletalov\u00e1 O, et al. Guideline for the diagnosis and therapy of myasthenia gravis. Czech Slovak Neurol Neurosurg. 2012;75:242\u201352.","journal-title":"Czech Slovak Neurol Neurosurg"},{"key":"682_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100063","author":"J Chen","year":"2020","unstructured":"Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac. 2020. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100063.","journal-title":"Lancet Reg Health West Pac"},{"key":"682_CR20","doi-asserted-by":"publisher","DOI":"10.14735\/AMCSNN2019171","author":"M Hor\u00e1kov\u00e1","year":"2019","unstructured":"Hor\u00e1kov\u00e1 M, Martinka I, Voh\u00e1\u0148ka S, \u0160palek P, Bedna\u0159\u00edk J. A comparative study of myasthenic patients in the Czech and Slovak Republics. Ces Slov Neurol Neurochir. 2019. https:\/\/doi.org\/10.14735\/AMCSNN2019171.","journal-title":"Ces Slov Neurol Neurochir"},{"key":"682_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.02.002","author":"A Mevius","year":"2023","unstructured":"Mevius A, J\u00f6res L, Biskup J, et al. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul Disord. 2023. https:\/\/doi.org\/10.1016\/j.nmd.2023.02.002.","journal-title":"Neuromuscul Disord"},{"key":"682_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018. https:\/\/doi.org\/10.1177\/1756285617749134.","journal-title":"Ther Adv Neurol Disord"},{"key":"682_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.1.16","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000. https:\/\/doi.org\/10.1212\/wnl.55.1.16.","journal-title":"Ann Thorac Surg"},{"key":"682_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB. The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e.","journal-title":"Neurology"},{"key":"682_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21609","author":"TM Burns","year":"2010","unstructured":"Burns TM, Grouse CK, Conaway MR, et al. Hobson-Webb LD, Tucker-Lipscomb B, et al. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010. https:\/\/doi.org\/10.1002\/mus.21609.","journal-title":"Muscle Nerve"},{"key":"682_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21053","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, et al. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008. https:\/\/doi.org\/10.1002\/mus.21053.","journal-title":"Muscle Nerve"},{"key":"682_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23964","author":"NM Alkhawajah","year":"2013","unstructured":"Alkhawajah NM, Oger J. Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve. 2013. https:\/\/doi.org\/10.1002\/mus.23964.","journal-title":"Muscle Nerve"},{"key":"682_CR28","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2174\/156652409789839116","volume":"9","author":"P McCombe","year":"2009","unstructured":"McCombe P, Greer J, Mackay I. Sexual dimorphism in autoimmune disease. Curr Mol Med. 2009;9:1058\u201379.","journal-title":"Curr Mol Med"},{"key":"682_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.604000","author":"R Shepherd","year":"2021","unstructured":"Shepherd R, Cheung AS, Pang K, Saffery R, Novakovic B. Sexual dimorphism in innate immunity: the role of sex hormones and epigenetics. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2020.604000.","journal-title":"Front Immunol"},{"key":"682_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2015.01.022","author":"S Blum","year":"2015","unstructured":"Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015. https:\/\/doi.org\/10.1016\/j.jocn.2015.01.022.","journal-title":"J Clin Neurosci"},{"key":"682_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-129","author":"S Twork","year":"2010","unstructured":"Twork S, Wiesmeth S, Klewer J, P\u00f6hlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010. https:\/\/doi.org\/10.1186\/1477-7525-8-129.","journal-title":"Health Qual Life Outcomes"},{"key":"682_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000034","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014. https:\/\/doi.org\/10.1097\/CND.0000000000000034.","journal-title":"J Clin Neuromuscul Dis"},{"key":"682_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1602489","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, Str\u00f6bel P, Mazia C, Oger J, Cea JG, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016. https:\/\/doi.org\/10.1056\/nejmoa1602489.","journal-title":"N Engl J Med"},{"key":"682_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00383-019-04441-0","author":"AG Kim","year":"2019","unstructured":"Kim AG, Upah SA, Brandsema JF, Yum SW, Blinman TA. Thoracoscopic thymectomy for juvenile myasthenia gravis. Pediatr Surg Int. 2019. https:\/\/doi.org\/10.1007\/s00383-019-04441-0.","journal-title":"Pediatr Surg Int"},{"key":"682_CR35","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2017.17009","author":"NF Mcsweyn","year":"1954","unstructured":"Mcsweyn NF, Schwarz H. Thymectomy in myasthenia gravis. Can Med Assoc J. 1954. https:\/\/doi.org\/10.5152\/eurasianjmed.2017.17009.","journal-title":"Can Med Assoc J"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00682-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T16:19:00Z","timestamp":1737821940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00682-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00682-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Petr H\u00e1jek and Jacek Cudny are employees of UCB Pharma. Katar\u00edna Brecikov\u00e1 and Ale\u0161 Tichop\u00e1d are employees of CEEOR company, which was contracted by UCB Pharma to conduct the analyses. Stanislav Voh\u00e1\u0148ka, Magda Hor\u00e1kov\u00e1, Jana Junkerov\u00e1, Michala Jakub\u00edkov\u00e1, Ji\u0159\u00ed Pi\u0165ha, Michaela T\u00fdblov\u00e1 and Daniela Vla\u017en\u00e1 claim they have no conflict of interest. The technical and analytical management of the register is provided by the Institute of Biostatistics and Analyses, s.r.o., which is also the processor of personal data within the register. CEEOR s.r.o. and IBA s.r.o. are commercial research organisations conducting observational studies. The following study centers participated on collection of data used in this work: University Hospital Brno\u2014Department of Neurology, University Hospital Prague- Motol\u2014Department of Child Neurology, University Hospital Ostrava\u2014Department of Child Neurology, University Hospital Prague- Motol\u2014Department of Neurology of the 2. Med. Faculty, University Hospital Ostrava\u2014Department of Child Neurology, University Hospital Ostrava\u2014Department of Neurology, University Hospital Plze\u0148\u2014Department of Neurology, Thomayer University Hospital Prague\u2014Department of Neurology, University Hospital Hradec Kr\u00e1lov\u00e9\u2014Department of Neurology, University Hospital Prague- Kr\u00e1lovsk\u00e9 Vinohrady\u2014Department of Neurology, Hospital of the Pardubice region\u2014Department of Neurology, Masaryk\u2019s hospital in \u00dast\u00ed nad Labem\u2014Neurology department, Hospital \u010cesk\u00e9 Bud\u011bjovice\u2014Neurology department, Hospital in Teplice\u2014Neurology department, General University Hospital Prague\u2014Department of Neurology. University Hospital Brno and University Hospital Prague- Motol are members of the European Reference Network for Neuromuscular Diseases- Project ID 870177.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Ethics Committee of the University Hospital in Brno under the number 06-160518. All participants signed an informed consent. We confirm that this study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All authors had permission to use MyReg register.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}